Cormorant Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Cormorant Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.29M	Sell	100,000 -125,000	-56%	-$7.99M	0.32%	37
2026 Q1	$15.8M	Sell	225,000 -25,000	-10%	-$1.75M	0.79%	30
2025 Q4	$20.5M	Sell	250,000 -50,000	-17%	-$3.73M	0.95%	23
2025 Q3	$17.8M	Hold	300,000	–	–	1.23%	21
2025 Q2	$12.2M	Sell	300,000 -100,000	-25%	-$4.5M	0.91%	24
2025 Q1	$20.5M	Sell	400,000 -100,000	-20%	-$4.94M	1.55%	19
2024 Q4	$27.7M	Hold	500,000	–	–	1.52%	20
2024 Q3	$16.4M	Hold	500,000	–	–	0.87%	33
2024 Q2	$13.6M	Sell	500,000 -1,639,102	-77%	-$55.1M	0.79%	33
2024 Q1	$77.8M	Sell	2,139,102 -82,320	-4%	-$2.42M	3.41%	8
2023 Q4	$45M	Sell	2,221,422 -400,000	-15%	-$6.68M	2.15%	12
2023 Q3	$46.6M	Buy	2,621,422 +1,200,000	+84%	+$21.2M	2.72%	11
2023 Q2	$25.7M	Hold	1,421,422	–	–	1.44%	20
2023 Q1	$17.9M	Sell	1,421,422 -315,000	-18%	-$4.61M	1.18%	23
2022 Q4	$25.5M	Sell	1,736,422 -235,000	-12%	-$3.89M	1.7%	19
2022 Q3	$33.8M	Buy	1,971,422 +96,422	+5%	+$1.53M	2.36%	12
2022 Q2	$27.4M	Buy	1,875,000 +499,018	+36%	+$7.49M	2.07%	16
2022 Q1	$23.1M	Sell	1,375,982 -27,349	-2%	-$508K	1.78%	15
2021 Q4	$31.6M	Sell	1,403,331 -41,500	-3%	-$1.08M	1.88%	16
2021 Q3	$31.1M	Sell	1,444,831 -69,438	-5%	-$1.72M	1.27%	24
2021 Q2	$43.9M	Sell	1,514,269 -200,000	-12%	-$6.25M	1.49%	22
2021 Q1	$55.3M	Hold	1,714,269	–	–	1.23%	20
2020 Q4	$70M	Buy	+1,714,269	New	+$48.8M	1.67%	22

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cormorant Asset Management's TARS Position: Q2 2026 in Review

Cormorant Asset Management reduced its Tarsus Pharmaceuticals (TARS) stake by 56% in Q2 2026, selling an estimated $7.99M and leaving 100,000 shares worth $6.29M. The position accounts for 0.32% of the portfolio, ranked #37.

Cormorant Asset Management first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $77.8M in Q1 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Cormorant Asset Management held 100,000 shares of Tarsus Pharmaceuticals worth $6.29M as of Q2 2026.
Cormorant Asset Management sold 125,000 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $7.99M.
Tarsus Pharmaceuticals made up 0.32% of Cormorant Asset Management's portfolio in Q2 2026, its #37 holding.
Cormorant Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
Cormorant Asset Management's Tarsus Pharmaceuticals position peaked at $77.8M in Q1 2024.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.